Piotr J Bachul, Karolina Golab, Lindsay Basto, Steven Zangan, Jordan S Pyda, Angelica Perez-Gutierrez, Peter Borek, Ling-Jia Wang, Martin Tibudan, Dong-Kha Tran, Roi Anteby, Gabriela S Generette, Jędrzej Chrzanowski, Wojciech Fendler, Laurencia Perea, Kumar Jayant, Aaron Lucander, Celeste Thomas, Louis Philipson, J Michael Millis, John Fung, Piotr Witkowski
A recent randomized, multicenter trial did not show benefit of a CXCR1/2 receptor inhibitor (Reparixin) when analysis included marginal islet mass (>3,000 IEQ/kg) for allotransplantation and when immunosuppression regimens were not standardized among participating centers. We present a post-hoc analysis of trial patients from our center at the University of Chicago who received an islet mass of over 5,000 IEQ/kg and a standardized immunosuppression regimen of anti-thymocyte globulin (ATG) for induction. Twelve islet allotransplantation (ITx) recipients were randomized (2:1) to receive Reparixin ( N = 8) or placebo ( N = 4) in accordance with the multicenter trial protocol...
January 2021: Cell Transplantation